Article

Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphoma

2020-09-23

Abstract excerpt

In recent years, chimeric antigen receptor (CAR) T cell therapy has shown great promise in treating hematological malignancies. However, using virus in manufacture of CAR T cells brings about several problems. The application of CRISPR/Cas9 genome editing technology emerges in constructing novel CAR T cells by disrupting endogenous genes. Here we successfully develop a two-in-one approach to generate non-viral gen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 35f416fd-12b2-5e40-a15f-0669730689ab
DOI: 10.1101/2020.09.22.20199786

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphomaDOI 10.1101/2020.09.22.20199786Read

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaSemantic proximity Read

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphomaSemantic proximity Read

Strengthening the CAR-T Cell Therapeutic Application using CRISPR/Cas9 TechnologySemantic proximity Read

Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technologySemantic proximity Read

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challengesSemantic proximity Read

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesSemantic proximity Read

A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9Semantic proximity Read

Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotypeSemantic proximity Read

The Past, Present, and Future of Non-Viral CAR T CellsSemantic proximity Read

The progress of CAR-T therapy in cancer and beyondSemantic proximity Read

A carrier-free multiplexed gene editing system applicable for suspension cellsSemantic proximity Read

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene EditingSemantic proximity Read